CD38 and congenital rubella syndrome: These findings are highly indicative of the potential initiation of a cytokine release syndrome (CRS) by CD38- or SLAMF7-directed bispecific antibodies, a life-threatening clinical situation and a major drawback of current T cell engaging strategies.